fibrosis - InSphero


May 1, 2020
NASH model treatments

Experimental Design Considerations for NASH Drug Screening

An ongoing challenge in NASH Drug Discovery is selecting “fit for purpose” models for preclinical drug screening. InSphero liver expert Sue Grepper and Head of Liver Solutions Eva Thoma recently […]
December 18, 2019
Scalable Akura Plate Technology

InSphero marks 10 years of innovation in 3D cell-based technology

InSphero CEO Jan Lichtenberg muses about how far 3D cell-based technology has come since InSphero was founded in 2009 and shares the latest news about how our disruptive 3D technology […]
September 23, 2019
Microtissue illustration

Can an in vitro NASH endpoint be truly predictive of the in vivo response?

Model systems, whether laboratory animals or human cell-based systems, have long been central to the discovery and development of new and better drugs for the treatment of human disease. But […]
July 30, 2019
Mouse on a plate

Are Animal NASH models slowing us down?

InSphero Senior Application Scientist Sue Grepper explains why critical limitations of dietary and genetically modified rodent models for NASH may be slowing down drug discovery efforts in this blog.  She […]
July 17, 2019
Scalable Akura Plate Technology

Scaling in vitroNASH models to find a cure for NASH

InSphero CEO Jan Lichtenberg and renowned liver disease expert Dr. Scott Friedman of the Icahn School of Medicine at Mount Sinai recently talked to PharmaExec magazine about how to resolve […]
August 20, 2018

Can 3D in vitro models accelerate NASH and Fibrosis drug discovery?

Pharma companies racing to accelerate drug discovery for chronic liver diseases, such as NASH and fibrosis, need better preclinical testing tools for compound screening and mechanistic studies. Here's how next-generation […]